Publications by authors named "Michael Mauro"

Claim this Profile
E
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.
Ehab Atallah, Michael S Broder, Onyee Chan, Kathryn E Flynn, Jeffrey A Gilreath, Michael J Mauro

Hematology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How I Treat Advanced Phases of CML.
Michael J Mauro

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.
Antonino Glaviano, Ellen Weisberg, Hiu Y Lam, Donavan J J Tan, Andrew J Innes, Michael J Mauro

Nat Rev Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.
Michael J Mauro, Rüdiger Hehlmann, Loretta A Williams, Stuart L Goldberg, Mauricette Michallet

Leuk Lymphoma· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.
Michael J Mauro, Yosuke Minami, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.
Jane F Apperley, Dragana Milojkovic, Nicholas C P Cross, Henrik Hjorth-Hansen, Andreas Hochhaus, Michael Mauro

Leukemia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1 treated with at least 2 prior TKIs: Phase 1 final results.
Andreas Hochhaus, Dong-Wook Kim, Jorge E Cortes, Koji Sasaki, Michael J Mauro

Leukemia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.
Jorge E Cortes, Fabian Lang, Delphine Rea, Andreas Hochhaus, Massimo Breccia, Michael J Mauro

Leukemia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic profile of novel reduced-dose Danziten (nilotinib tablets) versus Tasigna (nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysis.
Michael Mauro, Jerald Radich, Paras Jain, David Sequeira, Francesco Bellanti

Cancer Chemother Pharmacol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial.
Ehab L Atallah, Michael J Mauro, Koji Sasaki, Moshe Y Levy, Paul Koller

Future Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Elias Jabbour, Jane Apperley, Jorge Cortes, Delphine Rea, Michael Deininger, Michael Mauro

Leukemia· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.
Camille Kockerols, Peter J M Valk, Stéphanie Dulucq, Franck-Emmanuel Nicolini, François-Xavier Mahon, Michael J Mauro

Am J Hematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germ fate determinants protect germ precursor cell division by reducing septin and anillin levels at the cell division plane.
Caroline Q Connors, Michael S Mauro, J Tristian Wiles, Andrew D Countryman, Sophia L Martin

Mol Biol Cell· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
Jorge E Cortes, Koji Sasaki, Dong-Wook Kim, Timothy P Hughes, Gabriel Etienne, Michael J Mauro

Leukemia· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Influence of Body Fat Dynamics on Pulmonary Immune Responses in Murine Tuberculosis: Unraveling Sex-Specific Insights.
Dhanya Dhanyalayam, Hariprasad Thangavel, Tabinda Sidrat, Neelam Oswal, Kezia Lizardo, Michael Mauro

Int J Mol Sci· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterning, regulation, and role of FoxO/DAF-16 in the early embryo.
Michael S Mauro, Sophia L Martin, Julien Dumont, Mimi Shirasu-Hiza, Julie C Canman

bioRxiv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CML and the WHO: Why?
Ellin Berman, Neil P Shah, Michael Deninger, Jessica K Altman, Maria Amaya, Michael Mauro

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Elias Jabbour, Jane Apperley, Jorge Cortes, Delphine Rea, Michael Deininger, Michael Mauro

Leukemia· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Project Confirm: Accelerated Drug Approvals for CML-Response.
Kendra L Sweet, Jorge E Cortes, Jane F Apperley, Mel Mann, Michael J Mauro

Clin Cancer Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
Aaron N Winn, Ehab Atallah, Jorge Cortes, Michael W N Deininger, Vamsi Kota, Michael J Mauro

JAMA Netw Open· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germ fate determinants protect germ precursor cell division by restricting septin and anillin levels at the division plane.
Caroline Q Connors, Michael S Mauro, J Tristian Wiles, Andrew D Countryman, Sophia L Martin

bioRxiv· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Neil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, Sarah M Larson, Susanne Saussele, Michael J Mauro

Br J Haematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.
Nobuko Hijiya, Michael J Mauro

Cancer Manag Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib.
Jorge E Cortes, Delphine Rea, Michael J Mauro, Diana Tran, Pearl Wang

J Med Econ· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
Delphine Réa, Carla Boquimpani, Michael J Mauro, Yosuke Minami, Alex Allepuz

Leukemia· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis